Get the Stockscreener App
34.49
2.10%
0.71
Arrowhead Pharmaceuticals Inc stock is traded at $34.49, with a volume of 2.53M.
It is up +2.10% in the last 24 hours and up +56.56% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$33.78
Open:
$33.88
24h Volume:
2.53M
Relative Volume:
1.06
Market Cap:
$4.77B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-24.81
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
+6.12%
1M Performance:
+56.56%
6M Performance:
+170.72%
1Y Performance:
+78.06%
1-Day Range:
$33.55
$34.61
1-Week Range:
$31.45
$34.61
52-Week Range:
$9.57
$34.61
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
34.49 | 4.67B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals stock hits 52-week high at 34.53 USD By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals stock hits 52-week high at 34.53 USD - Investing.com India
Can Quantum Digital Vision India Ltd Beat EPS Estimates in the Next QuarterDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Ranking Arrowhead Pharmaceuticals Inc. among high performing stocks via toolsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year HighWhat's Next? - MarketBeat
13,500 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Moody Lynn & Lieberson LLC - MarketBeat
What technical models suggest about Arrowhead Pharmaceuticals Inc.’s comebackWeekly Trend Recap & Consistent Profit Alerts - newser.com
Arrowhead Pharmaceuticals Inc. (ARWR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why millennials buy Arrowhead Pharmaceuticals Inc. (HDP1) stockJuly 2025 Highlights & AI Forecast Swing Trade Picks - newser.com
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - inkl
Is Arrowhead Pharmaceuticals Inc a good long term investmentEarnings Forecast Updates & Free Significant Capital Appreciation - earlytimes.in
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock outperform small cap peersJuly 2025 Sector Moves & Safe Entry Point Alerts - newser.com
What analysts say about Arrowhead Pharmaceuticals Inc stockGap Up/Gap Down Analysis & Free Rapid Portfolio Appreciation - earlytimes.in
Is Arrowhead Pharmaceuticals Inc HDP1 a good long term investmentEarnings Miss Alerts & Capital Allocation Recommendations - earlytimes.in
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Decreased by Voya Investment Management LLC - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock outperform Dow Jones index2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
Can Arrowhead Pharmaceuticals Inc. stock deliver surprise earnings beatQuarterly Profit Report & Growth Focused Entry Reports - newser.com
Arrowhead Pharmaceuticals Hits New 52-Week High of $33.73 - Markets Mojo
Arrowhead Pharmaceuticals Hits New 52-Week High at $33.00 - Markets Mojo
Arrowhead Pharmaceuticals Hits New 52-Week High at $32.17 - Markets Mojo
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week HighWhat's Next? - MarketBeat
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45 - 富途牛牛
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year HighStill a Buy? - MarketBeat
Arrowhead Pharmaceuticals Hits New 52-Week High at $31.67 - Markets Mojo
Arrowhead Pharmaceuticals stock hits 52-week high at 31.7 USD By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals stock hits 52-week high at 31.7 USD - Investing.com
What is HC Wainwright's Estimate for ARWR FY2025 Earnings? - MarketBeat
Arrowhead Pharmaceuticals Hits New 52-Week High at $31.62 - Markets Mojo
Arrowhead Pharmaceuticals Hits Day High with 8.17% Surge in Stock Price - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $43.14 Average PT from Analysts - MarketBeat
Published on: 2025-09-21 07:04:10 - خودرو بانک
Market Recap: What is UBERs revenue forecastQuarterly Growth Report & Smart Investment Allocation Insights - khodrobank.com
Breakouts Watch: Can Arrowhead Pharmaceuticals Inc maintain its current growth ratePortfolio Update Report & Long-Term Investment Growth Plans - khodrobank.com
Aug Rallies: Is GIFI a top pick in the sectorQuarterly Profit Review & Daily Momentum Trading Reports - khodrobank.com
Rhumbline Advisers Has $4.41 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
James C. Hamilton Sells 15,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
Volume Summary: Whats next for BlackRock Health Sciences Trust stockMarket Sentiment Report & Weekly Chart Analysis and Guides - khodrobank.com
Big Picture: Whats the beta of Arrowhead Pharmaceuticals Inc stock2025 Price Momentum & Free High Accuracy Swing Entry Alerts - خودرو بانک
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 2,774,933 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Aug Outlook: Is Arrowhead Pharmaceuticals Inc stock a top performer YTDQuarterly Market Summary & Real-Time Buy Zone Alerts - khodrobank.com
Trading Action: What are Arrowhead Pharmaceuticals Incs recent SEC filings showingWatch List & Free Weekly Watchlist of Top Performers - خودرو بانک
What’s the fair value of Xeris Biopharma Holdings Inc. stockMarket Weekly Review & Capital Protection Trading Alerts - khodrobank.com
Analyst Downgrade: Is Imperial Petroleum Inc stock forming a triangle patternWeekly Stock Report & Long Hold Capital Preservation Tips - khodrobank.com
Earnings Report: Is Arrowhead Pharmaceuticals Inc forming a bullish divergence2025 Geopolitical Influence & Comprehensive Market Scan Reports - خودرو بانک
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Woodline Partners LP - MarketBeat
Treasury Yields: Will Satellogic Inc Equity Warrant stock benefit from M A2025 Retail Activity & Daily Profit Maximizing Trade Tips - خودرو بانک
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - MSN
4 Biotech Stocks at the Cutting Edge of Drug Delivery (MDCX, RNA, NBTX, ARWR) - MarketScreener
Arrowhead Pharmaceuticals : ICW 2025 ARO CFB - MarketScreener
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):